Physician profile
Jay S Herbst
NPI 1710047097
$1,344.55
in general payments reported to CMS, 2019-2025
18 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2021: $45.94 · 2022: $116 · 2023: $196 · 2024: $528 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $195.51 | 2023-2025 | Puraply, Simplimax, Novachor |
| Abbvie INC. | $157.84 | 2024-2025 | |
| Janssen Biotech, INC. | $131.08 | 2024 | Tremfya, Simponi Aria, Stelara |
| Genentech USA, INC. | $109.47 | 2019 | |
| Galderma Laboratories, L.P. | $95.05 | 2023-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $93.18 | 2023-2025 | Blu-U |
| Elekta, INC. | $77.24 | 2024 | Elekta Medical Linear Accelerator |
| Regeneron Healthcare Solutions, INC. | $75.75 | 2024 | Dupixent |
| Amgen INC. | $66.00 | 2023-2024 | Otezla |
| Biofrontera INC. | $62.84 | 2019-2025 | Bf-Rhodoled, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $57.48 | 2021-2025 | |
| Lilly USA, LLC | $46.66 | 2021-2023 | Olumiant, Taltz |
| Kerecis Limited | $41.77 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Pfizer INC. | $35.35 | 2022 | |
| Leo Pharma INC. | $32.14 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $27.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.36 | 2022 | |
| Mimedx Group, INC. | $18.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.